HemoSonics

How does #pointofcare viscoelastic testing translate into real savings? By enabling care teams to reduce RBCs, FFP, platelets, and cryo usage. That’s the measurable value of faster, more targeted #coagulation insight. Read more about the clinical need of point-of-care #viscoelastic testing for transfusions and blood management here: https://lnkd.in/e3Z2dFdz

For too long, managing obstetric hemorrhage with viscoelastic testing often meant using devices off-label and struggling to interpret complex results. That gap in care ends now. The Quantra® Hemostasis System with the QStat® Cartridge is the first and only viscoelastic testing platform FDA-cleared for peripartum obstetric procedures. Move from complexity to actionable, patient-specific data. With the Quantra System, gain on-label, point-of-need testing featuring: ✅ Built-in OB-Specific Reference Ranges: Context matters. ✅ Easy-to-Interpret Results in Minutes: Get clarity when seconds count. ✅ Automated Workflow: Only 30 seconds of hands-on time. Get Comprehensive Hemostasis Insights: ✅ Clot Time (CT) in ~2.5 min ✅ Fibrinogen Contribution (FCS) in ~12.5 min ✅ True Clot Lysis (CSL), measured against a control Equip your team with the system designed for the delivery room. Standardize excellence in #maternalcare and make informed decisions with confidence. #Obstetrics #MaternalHealth #Hemostasis

Yes the Quantra System delivers results fast, but here's a tip... If you’re considering a hemostasis analyzer for time-savings, think beyond results: > How much hands-on time does it need? > How quick is it to load a sample? > How much extra time is spent transferring samples to the lab if the device isn't available at the point of care? > How much time is spent interpreting results or waiting for trained staff? Every minute saved is time back for your care teams, and for your patients. The Quantra System not only delivers fast results, it also minimizes hands-on time, simplifies sample prep, and reduces delays waiting for lab transfers or specialized staff. See it for yourself: https://hemosonics.com/ #HealthcareEfficiency #PointOfCareTesting #Hemostasis #MedTech #PatientCare

Every patient facing serious bleeding is someone’s parent, partner, friend, sibling, or child. Clinicians know this better than anyone. They carry the responsibility of bleeding management, where each choice can ripple through a patient’s life and family. The pressure is intense, with sometimes only minutes to make the right call, and a lot of complex information to weigh. They shouldn’t have to shoulder that pressure alone. The Quantra® System was designed to give clinicians clear hemostasis answers in the moment, so they can make confident, data-driven decisions. Visit our webite to learn more: https://hemosonics.com #BleedingManagement #PatientSafety #HealthcareInnovation #Quantra

Hospitals need more than technology to optimize bleeding management. They need a partner that will provide end-to-end clinical and operational support to help confidently launch, scale, and get the most from their viscoelastic testing programs. Ready to lead the VET conversation at your facility? Head to our website for more information about available support from our team, or download the free guide, "The Champion’s Guide to Launching a Viscoelastic Testing Program." https://hemosonics.com/ #ViscoelasticTesting #BleedingManagement #Quantra

The FDA has cleared the Quantra® Hemostasis System with QStat® Cartridge for use in peripartum obstetric procedures — making it the first and only FDA-cleared viscoelastic testing (VET) system for OB care. This matters. The United States continues to have the highest rate of maternal deaths of any high-income nation*. The Quantra System puts the health of mothers at the center, and sets a new standard of care to help save lives. Until now, VET devices used in cases of obstetric bleeding were off-label. Now, with the Quantra System, clinicians finally have an FDA-cleared solution designed to deliver rapid, actionable insights at the point of need. At HemoSonics, we are proud to stand at the forefront of innovation in bleeding management. We’re committed to fighting the maternal mortality crisis by advancing technology that helps women have safe and healthy deliveries. Read the press release for more on this breaking news: https://lnkd.in/eaY_CCUX #MaternalHealth #Obstetrics #FDAclearance #BreakingNews #MedicalInnovation #OBGYN #HospitalLeadership #PatientSafety *Source: Munira Z. Gunja et al., Insights into the U.S. Maternal Mortality Crisis: An International Comparison (Commonwealth Fund, June 2024). [https://lnkd.in/g384y2HM]